CN109601750A - 预防禽坏死性肠炎的绿色饲料添加剂及其制备方法 - Google Patents
预防禽坏死性肠炎的绿色饲料添加剂及其制备方法 Download PDFInfo
- Publication number
- CN109601750A CN109601750A CN201811447391.6A CN201811447391A CN109601750A CN 109601750 A CN109601750 A CN 109601750A CN 201811447391 A CN201811447391 A CN 201811447391A CN 109601750 A CN109601750 A CN 109601750A
- Authority
- CN
- China
- Prior art keywords
- group
- necrotic enteritis
- product
- fowl
- feed additive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000004232 Enteritis Diseases 0.000 title claims abstract description 22
- 230000001338 necrotic effect Effects 0.000 title claims abstract description 21
- 239000003674 animal food additive Substances 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims description 11
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims abstract description 18
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims abstract description 18
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims abstract description 16
- 230000002265 prevention Effects 0.000 claims abstract description 14
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims abstract description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000005711 Benzoic acid Substances 0.000 claims abstract description 9
- 235000010233 benzoic acid Nutrition 0.000 claims abstract description 9
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000005770 Eugenol Substances 0.000 claims abstract description 8
- 235000019482 Palm oil Nutrition 0.000 claims abstract description 8
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000000654 additive Substances 0.000 claims abstract description 8
- 230000000996 additive effect Effects 0.000 claims abstract description 8
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 claims abstract description 8
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000007746 carvacrol Nutrition 0.000 claims abstract description 8
- 229960002217 eugenol Drugs 0.000 claims abstract description 8
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000002540 palm oil Substances 0.000 claims abstract description 8
- 239000005844 Thymol Substances 0.000 claims abstract description 7
- 229960000790 thymol Drugs 0.000 claims abstract description 7
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 238000002844 melting Methods 0.000 claims description 5
- 230000008018 melting Effects 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000000155 melt Substances 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 2
- 241000246358 Thymus Species 0.000 claims 1
- 235000007303 Thymus vulgaris Nutrition 0.000 claims 1
- 239000001585 thymus vulgaris Substances 0.000 claims 1
- 241000193468 Clostridium perfringens Species 0.000 abstract description 24
- 241000894006 Bacteria Species 0.000 abstract description 22
- 241000224483 Coccidia Species 0.000 abstract description 18
- 210000003250 oocyst Anatomy 0.000 abstract description 9
- 230000000968 intestinal effect Effects 0.000 abstract description 7
- 230000006378 damage Effects 0.000 abstract description 6
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 5
- 208000027418 Wounds and injury Diseases 0.000 abstract description 4
- 208000014674 injury Diseases 0.000 abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 230000008439 repair process Effects 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 49
- 241000287828 Gallus gallus Species 0.000 description 24
- 235000013330 chicken meat Nutrition 0.000 description 22
- 239000002574 poison Substances 0.000 description 22
- 231100000614 poison Toxicity 0.000 description 22
- 239000006030 antibiotic growth promoter Substances 0.000 description 20
- 235000014590 basal diet Nutrition 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 12
- 229960005486 vaccine Drugs 0.000 description 11
- 235000013601 eggs Nutrition 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 244000144977 poultry Species 0.000 description 10
- 235000013594 poultry meat Nutrition 0.000 description 10
- 230000003902 lesion Effects 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 241000252983 Caecum Species 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 210000004534 cecum Anatomy 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 208000027503 bloody stool Diseases 0.000 description 3
- 238000013401 experimental design Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229930191564 Monensin Natural products 0.000 description 2
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000004913 chyme Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- NJCUSQKMYNTYOW-MWUYRYRWSA-N enramicina Chemical compound O.N1C(=O)NC(=O)C(C=2C=C(Cl)C(O)=C(Cl)C=2)NC(=O)C(CO)NC(=O)C(C=2C=CC(O)=CC=2)NC(=O)C(CC2N=C(N)NC2)NC(=O)C(CCCNC(N)=O)NC(=O)C(C(C)O)NC(=O)C(C=2C=CC(O)=CC=2)NC(=O)C(C=2C=CC(O)=CC=2)NC(=O)C(C(C)O)NC(=O)N(CCCCN)C(=O)C(C=2C=CC(O)=CC=2)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)/C=C/C=C/CCCCC(C)CC)C(C)OC(=O)C(C=2C=CC(O)=CC=2)NC(=O)C(C)NC(=O)C1CC1CNC(N)=N1 NJCUSQKMYNTYOW-MWUYRYRWSA-N 0.000 description 2
- 108700041171 enramycin Proteins 0.000 description 2
- 229950003984 enramycin Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 229960005358 monensin Drugs 0.000 description 2
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 206010061043 Clostridial infection Diseases 0.000 description 1
- 208000037384 Clostridium Infections Diseases 0.000 description 1
- 241000223934 Eimeria maxima Species 0.000 description 1
- 241000499563 Eimeria necatrix Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- MVTQIFVKRXBCHS-SMMNFGSLSA-N N-[(3S,6S,12R,15S,16R,19S,22S)-3-benzyl-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide (10R,11R,12E,17E,19E,21S)-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),6,12,17,19,25(28)-hexaene-2,8,14,23-tetrone Chemical compound CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c2coc(CC(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@H]1C)n2.CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H]2CC(=O)CCN2C(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@@H]2CCCN2C1=O)c1ccccc1 MVTQIFVKRXBCHS-SMMNFGSLSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010080702 Virginiamycin Proteins 0.000 description 1
- 239000004188 Virginiamycin Substances 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960003842 virginiamycin Drugs 0.000 description 1
- 235000019373 virginiamycin Nutrition 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Birds (AREA)
- Inorganic Chemistry (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
Abstract
本发明涉及一种预防禽坏死性肠炎的绿色饲料添加剂,所述的添加剂包括百里香酚、香芹酚、丁香酚、苯甲酸、丁酸、二氧化硅和棕榈油。采用了本发明的预防禽坏死性肠炎的绿色饲料添加剂,抑制产气荚膜梭菌等有害菌,增加有益菌,维护肠道菌群平衡;减少球虫卵囊数;修复肠道损伤;提高抵抗力;协同增效,促生长、重修复、抗炎症、调免疫。
Description
技术领域
本发明涉及饲料添加剂领域,尤其涉及禽用饲料添加剂,具体是指一种预防禽坏死性肠炎的绿色饲料添加剂及其制备方法。
背景技术
由产气荚膜梭菌异常增殖引发的坏死性肠炎(NE)为全球家禽生产中影响肠道健康的最常见疾病之一,急性NE主要导致患病家禽急速死亡,死亡率高达50%;亚临床型NE主要导致生产性能下降、加工时废弃率上升等。全球每年因NE所致的养鸡业经济损失高达20亿美元(J.M.Diza Carrasco,2016)。产气荚膜梭菌是禽肠道的常在菌,只有在一些预置因素的影响下才会异常增殖而引起发病,这些预置因素包括日粮(如高非淀粉多糖、高蛋白日粮等)、微生物(如球虫等)、应激、免疫状态等。其中,球虫与产气荚膜梭菌互为预置因素,在临床上球虫感染总是与NE相伴的(蔡建平,2012)。
针对家禽NE,除了饲料营养、环境控制、饲养管理、疫苗预防等措施外,预防促生长用抗生素AGPs(Antibiotic growth promoters)是第一选择。AGPs自20世纪50年代开始在动物生产中应用,至今已有60多年的历史。有报道说,美国每年生产的抗生素约有45%用于饲用,而约80%家禽、75%猪、60%肉牛及75%奶牛都曾用过AGPs(杨波,2007)。据调查推算,中国每年生产抗生素原料约21万吨,其中9.7万吨用于畜牧养殖业,占年总产量的46.1%。但对AGPs应用的合理性,从一开始就争论不休,焦点是其对人体健康的危害和对环境的污染。随着长期超剂量不合理使用AGPs,不严格执行休药期,甚至使用违禁药物,耐药菌的产生、畜禽疾病难治、抗生素在畜产品和环境中残留等问题对公共健康构成了严重的威胁。当前,各国正在逐步采取严厉的手段限制AGPs的使用。
此外,针对NE的主要致病原产气荚膜梭菌和球虫的第二选择就是疫苗。针对产气荚膜梭菌的疫苗主要有类毒素苗和基因工程苗(如多肽苗、亚单位苗、核酸苗、活载体苗、基因缺失苗等)(乔艺然,2015),类毒素苗应用较多,但免疫成本高,安全性、残留毒性、效能等都有不足。球虫疫苗主要是活卵囊苗和基因工程苗(亚单位苗、核酸苗等),活苗在生产中应用更多,但在使用中除了要保证疫苗质量外,还要注意每只鸡的接种剂量即免疫均匀度。同时,强毒苗引入新场后不易清除,弱毒苗在鸡舍环境中毒力逐渐增强,安全隐患较大。
因此,现有技术中NE防治存在问题:(1)抗生素防治造成细菌耐药性与抗生素残留问题;(2)疫苗预防存在较大的安全隐患;(3)针对此问题的理论研究较多,成型产品较少,而且绿色、高效、无残留、稳定性好的产品几乎空白。
发明内容
本发明的目的是克服了上述现有技术的缺点,提供了一种预防禽坏死性肠炎、维护肠道健康、促生长、提高免疫力从而提升养殖效益的绿色饲料添加剂及其制备方法。
为了实现上述目的,本发明一方面提供了一种预防禽坏死性肠炎的绿色饲料添加剂,其具有如下构成:
所述的添加剂包括百里香酚、香芹酚、丁香酚、苯甲酸、丁酸、二氧化硅和棕榈油。
较佳地,所述的添加剂包括以下质量比的组分:
本发明还提供了一种权利要求1或2所述的预防禽坏死性肠炎的绿色饲料添加剂的制备方法,所述的制备方法包括步骤:
(1)将称量好的百里香酚、香芹酚、丁香酚、苯甲酸、丁酸置于熔解罐中50℃熔解,得到均一的第一混合物;
(2)用载体二氧化硅吸附所述的第一混合物,吸附混合5~10min,形成固体颗粒,即第二混合物;
(3)将壁材棕榈油80℃熔解后,对第二混合物进行包衣、凝固,冷却形成包衣膜;
(4)将包衣完的物料经16目过筛,筛下物即为所述的饲料添加剂。
采用了本发明的绿色禽用饲料添加剂及其制备方法,可以有效抑制产气荚膜梭菌等有害菌,增加有益菌,维护肠道菌群平衡;减少球虫卵囊数;修复肠道损伤;提高抵抗力,协同增效,促生长、重修复、抗炎症、调免疫、提高抵抗力,从而提升养殖效益。
附图说明
图1为本发明的饲料添加剂的制备方法的流程示意图。
图2~3为本发明的饲料添加剂在不同消化道的释放情况示意图。
图4为本发明的饲料添加剂的存储稳定性示意图。
图5为本发明的饲料添加剂对鸡源产气荚膜梭菌、大肠杆菌、肠炎沙门氏菌的抑制效果示意图。
具体实施方式
为了能够更清楚地描述本发明的技术内容,下面结合具体实施例来进行进一步的描述。
本发明提供了一种预防禽坏死性肠炎的绿色饲料添加剂,所述的饲料添加剂包括百里香酚、香芹酚、丁香酚、苯甲酸、丁酸、二氧化硅和棕榈油。
其中,所述的饲料添加剂包括以下质量比的组分:
所述的饲料添加剂的制备过程包括步骤:
称量百里香酚、香芹酚、丁香酚、苯甲酸、丁酸,置于溶解罐中50℃熔解为液体组分,形成第一混合物;
再用载体二氧化硅吸附第一混合物,吸附混合5~10min,形成固体颗粒,即第二混合物;
将壁材棕榈油80℃熔解后,对固体颗粒进行包衣、凝固,在固体颗粒表面形成包衣膜。将包衣完的物料经16目过筛,筛下物即为所述的预防禽坏死性肠炎的绿色饲料添加剂。
其中,所述的饲料添加剂为白色颗粒。所述的饲料添加剂为具有缓释作用、能作用于整个消化道且重点作用于后肠道的饲料添加剂。
本发明还提供了一种饲料,所述的饲料包括所述的预防禽坏死性肠炎的绿色饲料添加剂。
以下通过实施例对本发明的产品进行进一步说明。
实施例1:
采用以下质量比的组分制备本发明的饲料添加剂:
百里香酚11%、香芹酚11%、丁香酚10%、苯甲酸8%、丁酸5%、二氧化硅25%、棕榈油30%。
将称量好的植物精油、有机酸,置于熔解罐中熔解,得到均一的第一混合物;用二氧化硅吸附第一混合物,形成固体颗粒,即第二混合物;将棕榈油熔解后,对第二混合物进行包衣、凝固,冷却形成包衣膜;将包衣完的物料经16目过筛,筛下物即为本发明产品的具体实施例。
实施例2:
上述实施例1中的产品在模拟家禽消化道环境中的释放情况:
如图2~3所示,经过该工艺处理后的产品在家禽消化道不同部位表现出了较好的缓释效果,在胃中释放率约15~20%,在肠道释放率约80~85%,能够达到缓释效果。
实施例3:
上述实施例1产品50℃下存放时的存储(热)稳定性:
如图4所示,本发明产品主成分含量与配方值的比值变化缓慢,在20周时仍然高于95%,说明产品在50℃条件下稳定性好。
实施例4:
上述实施例1产品的使用效果评估:
1)对产气荚膜梭菌等有害菌的体外抑制效果
图5显示了本发明产品对禽源产气荚膜梭菌、大肠杆菌、肠炎沙门氏菌的抑菌圈直径,同时与恩拉霉素体外抑菌效果进行比较。从图4可知,本发明产品对禽源产气荚膜梭菌、大肠杆菌、肠炎沙门氏菌均高度敏感(抑菌圈直径20mm以上),恩拉霉素对产气荚膜梭菌中度敏感(抑菌圈直径15~20mm)。可见,本发明产品体外抑制产气荚膜梭菌的效果优于恩拉霉素。
2)动物试验一:
上述实施例1产品对肉鸡球虫、产气荚膜梭菌感染的影响
试验设计:将240只AA+肉公鸡随机分为3个处理组,包括基础日粮组、基础日粮+AGPs(80g/T 50%维吉尼亚霉素预混剂+500g/T 20%莫能菌素预混剂)组、基础日粮+产品(800g/T)组,每组8个重复,其中4个重复不攻毒,其余4个重复攻毒,每个重复10只鸡。
攻毒处理的鸡只在d 12分别灌服混合型球虫活疫苗(22000卵囊/mL,正常免疫的20倍量)1mL,d 21~23连续灌服新鲜产气荚膜梭菌培养液(1×108cfu/mL)1mL/天,非攻毒处理的鸡只分别灌服等量的PBS缓冲液和培养基。球虫攻毒后第8天即d 20,收集各组的全部粪便,用麦克马斯特法进行卵囊计数。再从各组每个重复中随机选取2只鸡麻醉处死后采集盲肠及其内容物,-20℃保存,尽早匀浆并用胃蛋白酶消化,采用麦克马斯特法对匀浆中的卵囊进行计数。产气荚膜梭菌感染后第3、9、17天即d 26、32、40,从各组每个重复中随机选取2只鸡麻醉处死后采集盲肠食糜,-20℃保存,尽快用于细菌(包括产气荚膜梭菌、乳酸菌)计数。
试验结果:
A对生产性能的影响
结果表明:在d 1~21、d 22~42和d 1~42,本发明产品组料肉比均显著较基础日粮组低(P<0.05),与AGPs组相近(P>0.05);攻毒组平均采食量、平均体增重均较不攻毒组高,料肉比在前期相近,后期攻毒组较不攻毒组低。20倍球虫活疫苗攻毒情况下出现这种结果,推测本发明产品对球虫有作用,可以降低球虫发病风险、促进免疫效果。
B对球虫卵囊的影响
结果表明:球虫感染后第8天(d 20),本发明产品组、AGPs组的粪便和盲肠食糜中球虫卵囊数均较基础日粮组显著下降(P<0.05),且本发明产品组在卵囊减少方面较AGPs有明显优势。同时,不攻毒处理的鸡只卵囊排出量明显低于攻毒处理的,这一方面印证生产性能的结果,另一方面也暗示整个养殖环境中可能存在隐性球虫感染,因为不攻毒的各组均检测出卵囊数。
C对肠道菌群的影响
结果表明:产气荚膜梭菌感染后第9天(d 32)、第17天(d 40),本发明产品组盲肠中乳酸菌数与产气荚膜梭菌数的比值(有益菌/有害菌)明显较AGPs组、基础日粮组高(P<0.05),攻毒后第3天(d 26)此比值在三个组间无明显差异。从日龄来看,本发明产品组比值在攻毒后第3、9、17天呈增加趋势,AGPs组先减后增,基础日粮组在d 40才略有增加。可见,本发明产品可抑制产气荚膜梭菌、促进有益菌。
3)动物试验二:
上述实施例1产品不同添加水平对肉鸡坏死性肠炎(球虫、产气荚膜梭菌感染)的影响试验设计:将504只AA+肉公鸡随机分为6个处理组,包括阴性对照组(基础日粮,不攻毒)、阳性对照组(基础日粮,攻毒)、AGPs组【基础日粮+AGPs(200g/T 15%亚甲基水杨酸杆菌肽+500g/T 20%莫能菌素预混剂,攻毒】、200g/T产品组(基础日粮+200g/T产品,攻毒)、500g/T产品组(基础日粮+500g/T产品,攻毒)、800g/T产品组(基础日粮+800g/T产品,攻毒),每组7个重复,每个重复12只鸡。在d 13,给攻毒组鸡只分别灌服1mL混合鸡球虫卵囊液(鸡巨型艾美耳球虫1.0×104个/mL、鸡毒害艾美耳球虫2.0×104个/mL),不攻毒组灌服等量的PBS缓冲液。分别收集球虫感染后第5天(d 18)的粪便,用麦克马斯特法进行卵囊计数。在球虫感染后第5-8天即d 18~21,分别给攻毒组鸡只连续灌服1mL/天新鲜培养的产气荚膜梭菌菌液(108cfu/mL),不攻毒组灌服等量的培养基。在d 28,从各组每个重复中随机选取1只体重接近的健康鸡只称重后剖杀,观察十二指肠、空肠、回肠病变并记分,收集盲肠内容物以供细菌计数。
A对生产性能的影响
结果表明:在d 1~21,本发明产品组料肉比没有表现出明显优势,梯度之间200g/T较低。在d 22~42,本发明产品200g/T组料肉比最低(P<0.05),且较抗生素组、阴性对照组低,500、800g/T产品组料肉比均较阳性对照组、阴性对照组低。全期来看料肉比,AGPs组料肉比最低,其次是阴性对照组,接着是本发明产品200、500、800g/T组,阳性对照组最高,且本发明产品200g/T组较阳性对照组差异显著(P<0.05)。可见,本发明产品可明显降低料肉比,尤其在后期阶段,200g/T也有明显效果。
B对肠道病变的影响
注:小肠总病变记分是综合十二指肠、空肠、回肠的病变记分计算而来。
结果表明:在产气荚膜梭菌攻毒后第7天(d 28),本发明产品组肠道病变情况显著轻于阳性对照组(P<0.05),随着添加量的增加,病变逐渐减少,尤其800g/T优于阴性对照组和AGPs组。在d 42,本发明500g/T产品组小肠病变记分最低,而AGPs组病变较高。可见,本发明产品可明显降低感染后的肠道损伤,效果优于AGPs。
C对球虫卵囊的影响
结果表明:在球虫感染后第5天(d 18),本发明产品组粪便中球虫卵囊数较阳性对照组显著降低(P<0.05),但高于APGs组。这说明,本发明产品可明显减少球虫卵囊数,从而降低坏死性肠炎发生率。
D对肠道菌群的影响
结果表明:在产气荚膜梭菌感染后第7天(d 28),本发明产品组较阳性对照组显著降低盲肠中产气荚膜梭菌数量(P<0.05),但梯度之间差异不显著(P>0.05)。对于盲肠中乳酸菌,本发明产品组较阳性对照组显著增加(P<0.05),500g/T组高于AGPs组和阴性对照组,但均差异不显著(P>0.05)。可见,本发明产品可显著抑制产气荚膜梭菌,增加有益菌,200g/T也有效。
4)动物试验三:
上述实施例1产品对蛋鸡预防坏死性肠炎、提高生产性能的影响
试验设计:
试验地点江苏丰城某蛋鸡养殖场。该场由于养殖设备问题,青年鸡转入产蛋舍后10天左右出现球虫感染现象,继而引发坏死性肠炎。选择日龄相近的2栋蛋鸡(5.3万羽/栋),以栋为单位,随机分为对照组和本发明产品组。试验从转群后(d 100)开始,对照组饲喂基础日粮,本发明产品组饲喂基础日粮+500g/T本发明产品。试验期为d 100~165日龄。观察鸡群、粪便等情况,记录鸡群产蛋率、死淘等。
A对鸡群、粪便的影响
据试验负责人反映,对照组在d 111出现料便、轻微血便,d 116稀便较多;解剖鸡只发现,有的小肠中后段胀气明显,肠管浆膜有出血斑点,肠壁变薄;d 125后仍有少量稀便。试验组在d 115零星出现料便、轻微血便现象,稀便少见;在d 120后未发现料便、血便、稀便情况,粪便成型度好。
B对产蛋率、死淘的影响
结果表明:本发明产品组在d 165平均产蛋率较对照组高3%,试验期间平均日死淘显著降低。可见,本发明产品可减轻球虫感染后的损伤,有效预防坏死性肠炎,提升养殖效益。
采用了本发明中的预防禽坏死性肠炎的绿色饲料添加剂及相应的饲料,产品中植物精油具有抑菌(尤其G+菌)、抑制球虫、抗炎症、提高免疫力等功效;苯甲酸具有较好的抑菌作用;丁酸具有较好的抑菌作用,同时也是肠上皮细胞的优质能量来源,具有修复肠粘膜、促进肠粘膜分泌抗菌肽的作用,还可与植物精油协同增效;具有缓释效果,能够减少球虫卵囊数,修复球虫感染后的肠道损伤,多水平、全方位抑制产气荚膜梭菌,提高免疫力,有效预防坏死性肠炎。
在此说明书中,本发明已参照其特定的实施例作了描述。但是,很显然仍可以作出各种修改和变换而不背离本发明的精神和范围。因此,说明书和附图应被认为是说明性的而非限制性的。
Claims (3)
1.一种预防禽坏死性肠炎的绿色饲料添加剂,其特征在于,所述的添加剂包括百里香酚、香芹酚、丁香酚、苯甲酸、丁酸、二氧化硅和棕榈油。
2.根据权利要求1所述的预防禽坏死性肠炎的绿色饲料添加剂,其特征在于,所述的添加剂包括以下质量比的组分:
3.一种权利要求1或2所述的预防禽坏死性肠炎的绿色饲料添加剂的制备方法,其特征在于,所述的制备方法包括步骤:
(1)将称量好的百里香酚、香芹酚、丁香酚、苯甲酸、丁酸,置于熔解罐中50℃熔解,得到均一的第一混合物;
(2)用载体二氧化硅吸附所述的第一混合物,吸附混合5~10min,形成固体颗粒,即第二混合物;
(3)将壁材棕榈油80℃熔解后,对第二混合物进行包衣、凝固,冷却形成包衣膜;
(4)将包衣完的物料经16目过筛,筛下物即为所述的饲料添加剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811447391.6A CN109601750A (zh) | 2018-11-29 | 2018-11-29 | 预防禽坏死性肠炎的绿色饲料添加剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811447391.6A CN109601750A (zh) | 2018-11-29 | 2018-11-29 | 预防禽坏死性肠炎的绿色饲料添加剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109601750A true CN109601750A (zh) | 2019-04-12 |
Family
ID=66006003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811447391.6A Withdrawn CN109601750A (zh) | 2018-11-29 | 2018-11-29 | 预防禽坏死性肠炎的绿色饲料添加剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109601750A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020245121A1 (en) * | 2019-06-07 | 2020-12-10 | Dsm Ip Assets B.V. | Use of benzoic acid and essential oil compounds for improving growth performance |
CN112841133A (zh) * | 2021-02-01 | 2021-05-28 | 四川农业大学 | 一种蛋鸡小肠肠炎模型的构建方法 |
CN113940389A (zh) * | 2021-10-19 | 2022-01-18 | 广州微特加生物工程有限公司 | 一种柠檬醛和香芹酚复配组合物及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1301135A (zh) * | 1998-05-18 | 2001-06-27 | 阿克佐诺贝尔公司 | 含麝香草酚的天然物质在制作动物饲料中的用途 |
US6322825B1 (en) * | 1995-05-26 | 2001-11-27 | Ropapharm B.V. | Compositions containing thymol and carvacrol and methods of treating gastrointestinal infections with the compositions |
CN102987093A (zh) * | 2012-10-29 | 2013-03-27 | 安佑(中国)动物营养研发有限公司 | 一种饲用植物精油添加剂及其制备方法、用途 |
US20140037698A1 (en) * | 2011-01-21 | 2014-02-06 | Norel, S.A | Additives for animal food |
CN108157663A (zh) * | 2018-01-17 | 2018-06-15 | 上海美农生物科技股份有限公司 | 针对沙门氏菌的家禽用饲料添加剂及相应的饲料 |
-
2018
- 2018-11-29 CN CN201811447391.6A patent/CN109601750A/zh not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6322825B1 (en) * | 1995-05-26 | 2001-11-27 | Ropapharm B.V. | Compositions containing thymol and carvacrol and methods of treating gastrointestinal infections with the compositions |
CN1301135A (zh) * | 1998-05-18 | 2001-06-27 | 阿克佐诺贝尔公司 | 含麝香草酚的天然物质在制作动物饲料中的用途 |
US20140037698A1 (en) * | 2011-01-21 | 2014-02-06 | Norel, S.A | Additives for animal food |
CN102987093A (zh) * | 2012-10-29 | 2013-03-27 | 安佑(中国)动物营养研发有限公司 | 一种饲用植物精油添加剂及其制备方法、用途 |
CN108157663A (zh) * | 2018-01-17 | 2018-06-15 | 上海美农生物科技股份有限公司 | 针对沙门氏菌的家禽用饲料添加剂及相应的饲料 |
Non-Patent Citations (3)
Title |
---|
DAFEI YIN,等: "Supplemental thymol and carvacrol increases ileum Lactobacilluspopulation and reduces effect of necrotic enteritis caused by Clostridium perfringes in chickens", 《SCIENCETIFIC REPORTS》 * |
P. C. ARISTIMUNHA,等: "A blend of benzoic acid and essential oil compounds as an alternative to antibiotic growth promoters in broiler diets", 《THE JOUNAL OF APPLIED POULTRY RESEARCH》 * |
赵景鹏,等: "不同精油与酸化剂组合对肉仔鸡肠炎沙门氏菌感染的控制效果研究", 《动物营养学报》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020245121A1 (en) * | 2019-06-07 | 2020-12-10 | Dsm Ip Assets B.V. | Use of benzoic acid and essential oil compounds for improving growth performance |
CN112841133A (zh) * | 2021-02-01 | 2021-05-28 | 四川农业大学 | 一种蛋鸡小肠肠炎模型的构建方法 |
CN113940389A (zh) * | 2021-10-19 | 2022-01-18 | 广州微特加生物工程有限公司 | 一种柠檬醛和香芹酚复配组合物及其应用 |
CN113940389B (zh) * | 2021-10-19 | 2022-04-29 | 广州微特加生物工程有限公司 | 一种柠檬醛和香芹酚复配组合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gharib et al. | Comparison of the effects of probiotic, organic acid and medicinal plant on Campylobacter jejuni challenged broiler chickens | |
Kaoud | Effect of Spirulina platensis as a dietary supplement on broiler performance in comparison with prebiotics | |
CN102031235B (zh) | 一种粪肠球菌anse228及其应用 | |
Sadeghi et al. | Immune responses to dietary inclusion of prebiotic-based mannan-oligosaccharide and β-glucan in broiler chicks challenged with Salmonella enteritidis | |
Bai et al. | Co-supplementation of dietary seaweed powder and antibacterial peptides improves broiler growth performance and immune function | |
Ripon et al. | Dose-dependent response to phytobiotic supplementation in feed on growth, hematology, intestinal pH, and gut bacterial load in broiler chicken | |
CN109601750A (zh) | 预防禽坏死性肠炎的绿色饲料添加剂及其制备方法 | |
Abbas et al. | Effects of formic acid administration in the drinking water on production performance, egg quality and immune system in layers during hot season | |
CN105341363A (zh) | 一种畜禽用新型复合饲料添加剂 | |
CN111184140A (zh) | 一种提高蛋鹌鹑生产性能的饲料添加物 | |
Wu et al. | Effect of glutamine on the intestinal function and health of broilers challenged with Salmonella pullorum | |
CN110692863A (zh) | 一种提高罗非鱼保肝护肠能力的植物提取物饲料添加剂 | |
CN105744844A (zh) | 预防鸡雁小纲动物中坏死性肠炎的制剂 | |
Prudyus et al. | Morphological changes in the immune system organs of piglets fed with different feed additives. | |
KR20070045174A (ko) | 산란계, 육계 및 양돈에 대한 천연면역증강제의 제조방법 | |
Jung et al. | Oxygenated drinking water enhances immune activity in broiler chicks and increases survivability against Salmonella Gallinarum in experimentally infected broiler chicks | |
WO2025010846A1 (zh) | 溶血磷脂酸在防治猪感染性腹泻中的应用 | |
CN112841133B (zh) | 一种蛋鸡小肠肠炎模型的构建方法 | |
CN117064013A (zh) | 一种复合对虾饲料添加剂及其在对虾养殖中的应用 | |
CN101595945A (zh) | 一种促生产、增强动物抗病能力的饲料添加剂 | |
Ezema | Probiotic effects of Saccharomyces cerevisiae on laying chicken fed palm kernel cake-based diets | |
CN114507619A (zh) | 一种液态复合益生菌制剂、其制备方法以及其在改善腹泻和保肝护肝方面的应用 | |
Karimi | Effects of red seaweed (Palmaria palmata) supplemented diets fed to broiler chickens raised under Normal or stressed conditions | |
Montiel | Influence of feeding programs on innate and adaptive immunity in broiler breeders | |
Chamani | Efficacy of Bactocell® and Toyocerin® as probiotics on growth performance, blood parameters and intestinal morphometry of Turkey poults |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190412 |